Oncology Articles

What Happens when the Cost of Cancer Care Becomes Unsustainable?
Steven Simoens, Wim van Harten, Gilberto Lopes, Arnold Vulto, Klaus Meier, Nils Wilking
European Oncology & Haematology, 2017;13(2):Epub ahead of print
Can we Continue to Afford Access to Cancer Treatment?
Nils Wilking, Gilberto Lopes, Klaus Meier, Steven Simoens, Wim van Harten, Arnold Vulto
European Oncology & Haematology, 2017;13(2):Epub ahead of print
Targeting the FLT3 Mutation in Acute Myeloid Leukaemia
Sabine Kayser, Richard F Schlenk
European Oncology & Haematology, 2017;13(2):Epub ahead of print
Plasmacytic Post-transplant Lymphoproliferative Disorder – Case Report
Jiri Hanousek, Jakub Radocha, Ondrej Soucek, Lenka Pliskova, Katerina Kamaradova, Alzbeta Zavrelova, Pavel Zak
European Oncology & Haematology, 2017;13(1):80–2 DOI: https://doi.org/10.17925/EOH.2017.13.01.80
Molecular Diagnostics in Breast Cancer Routine Practice
Natalie D ter Hoeve, Cathy B Moelans, Willemijne AME Schrijver, Wendy de Leng, Paul J van Diest
European Oncology & Haematology, 2017;13(1):74–9 DOI: https://doi.org/10.17925/EOH.2017.13.01.74
Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy
Bruno Cadilha, Klara Dorman, Felicitas Rataj, Stefan Endres, Sebastian Kobold
European Oncology & Haematology, 2017;13(1):66–73 DOI: https://doi.org/10.17925/EOH.2017.13.01.66
Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis
Adenocarcinoma in situ of the Cervix – is Loop Electrosurgical Excision Procedure an Acceptable Alternative to Cold Knife Cone Biopsy?
The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians
Ahmet Emre Eskazan
European Oncology and Haematology, 2017;13(1):15–6 DOI: https://doi.org/10.17925/EOH.2017.13.01.15
Oncological Scenario in Developing Countries – Little Light at the End of Tunnel
Adenocarcinoma in situ of the Cervix – is Loop Electrosurgical Excision Procedure an Acceptable Alternative to Cold Knife Cone Biopsy?
Mila Pontremoli Salcedo, Anthony Costales, Mark F Munsell, Preetha Ramalingam, Ricardo Dos Reis, Andrea Milbourne, Patrícia El Beitune, Kathleen M Schmeler
European Oncology & Haematology, 2017;13(1):24–7 DOI: https://doi.org/10.17925/EOH.2017.13.01.24
Metastatic Prostate Cancer Manifesting as Cavernous Sinus Syndrome—Case Report and Review of the Literature
Brandon Kuiper, Aline Babikian, Wilfred Delacruz
Oncology & Hematology Review, 2017;13(1):59–63 DOI: https://doi.org/10.17925/OHR.2017.13.01.59
Targeting Cancer Stem Cells—A Renewed Therapeutic Paradigm
Catherine L Amey, Antoine E Karnoub
Oncology & Hematology Review, 2017;13(1):45–55 DOI: https://doi.org/10.17925/OHR.2017.13.01.45
Paraneoplastic Syndromes in Children with Hodgkin Lymphoma
Angela Punnett , Laura Betcherman
Oncology & Hematology Review, 2017;13(1):41–4 DOI: https://doi.org/10.17925/OHR.2017.13.01.41
Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia
Tarsheen K Sethi, Nishitha M Reddy
Oncology & Hematology Review, 2017;13(1):34–40 DOI: https://doi.org/10.17925/OHR.2017.13.01.34
Primary Tumor Location Implications on Biological Therapy in Metastatic Colorectal Cancer
Marwan Fakih
Oncology & Hematology Review, 2017;13(1):30–3 DOI: https://doi.org/10.17925/OHR.2017.13.01.30
Development of Checkpoint Inhibitors for Sarcomas
Rodrigo R Munhoz, William D Tap, Sandra P D’Angelo
Oncology & Hematology Review, 2017;13(1):25–9 DOI: https://doi.org/10.17925/OHR.2017.13.01.25
Can We Improve Thyroid Fine-needle Aspiration Cytology Adequacy in a Low-volume Thyroid Center?
Mohamed Shaaban, Mario Metry, Sebastian Aspinall
Oncology & Hematology Review, 2017;13(1):21-4 DOI: https://doi.org/10.17925/OHR.2017.13.01.21
Raising the Bar in Advanced Pancreatic Cancer
Sharlene Gill
Oncology & Hematology Review, 2017;13(1):19–20 DOI: https://doi.org/10.17925/OHR.2017.13.01.19
Decreasing Lung Cancer Mortality through Screening—The Lung Cancer Alliance Experience
Laurie Fenton Ambrose, Amy Copeland, Jennifer C King
Oncology & Hematology Review, 2017;13(1):17–8 DOI: https://doi.org/10.17925/OHR.2017.13.01.17